< Home

Services

Your ECVS

< Back

34th Annual Scientific Meeting proceedings


Stream:   |   Session: STS and Oncology Short Communications
Date/Time: 06-07-2024 (17:15 - 17:30)   |   Location: Auditorium 4
Comparison of a targeted anti-αvβ3 integrin NIR fluorescent probe and Indocyanin green for precision resection of naturally occurring soft tissue sarcomas in dogs. A pilot study.
Nolff MC*1, Chiti LE1, Grest P2, Beer P1
1Clinic for Small Animal Surgery, University of Zürich, Zürich, Switzerland, 2Institute of Veterinary Pathology, University of Zürich, Zürich, Switzerland.

Objectives:

Soft Tissue Sarcomas (STS) represent 10% of all diagnosed canine skin tumors in dogs. The mainstay of therapy is complete surgical resection and the most important prognostic factors are completeness of resection, tumor size and tumor grade. As direct visualization of the tumor borders during surgery is currently impossible, the highly infiltrative growth of STS leads to incomplete resections in up to 60% of dogs. Near Infrared (NIR) imaging might allow improved visualization of tumor margins during surgery to improve resection accuracy.

Methods:

Client-owned dogs (n=8) presented for primary resection of naturally occurring STS, or revision surgery (n=6) after incomplete STS resection were enrolled. Patients were randomized to receive AngiostampTM (AS) or indocyanine green (ICG) before surgery. Surgical resection under NIR guidance was performed in both groups with the surgeon blinded to treatment.

Results:

Mean time to revision surgery in dogs with recurrence was 171 days (22-478). Clear NIR signal demarcating the tumor was visible in 3/7 dogs in the ICG group, and 6/7 dogs in the AS group. False positive signal was detected in 4/6 dogs in the ICG group and 1/7 dogs with AS. All resections were R0, and at the time of writing (mean time after resection 100 days, range 9-205) none of the dogs had recurrence. No dye associated complications occurred.

Conclusions:

The initial results of this study indicate superiority of targeted dyes. The clinical impact of these results needs to be validated in a bigger cohort of cases.

Back to the top of the page ^